PFIZER LIMITED (IN:PFIZER)
:PFIZER
Want to see IN:PFIZER full AI Analyst Report?
Top Page
PFIZER LIMITED
(PFIZER)
Select Model
Select Model
Rating:64Neutral
Price Target:
₹4,929.00
▲(0.85% Upside)
Action:Reiterated
Date:05/14/26
The score is supported primarily by strong profitability and an exceptionally low-leverage balance sheet, indicating high financial resilience. This is tempered by weak technical momentum (price below key moving averages with negative MACD) and a relatively high P/E with a low dividend yield.
Positive Factors
Low Leverage / Strong Balance Sheet
Exceptionally low debt-to-equity (well below 0.10) provides durable financial resilience, enabling sustained R&D investment, stable supplier relationships, and flexible capital allocation. This structural strength reduces refinancing risk and supports operations through industry cycles.
Negative Factors
Uneven Revenue Trends
Choppy top-line performance across multiple years indicates demand or portfolio volatility and complicates forecasting. Persistent uneven revenue undermines planning for manufacturing, marketing scale, and R&D prioritization, increasing execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Strong Balance Sheet
Exceptionally low debt-to-equity (well below 0.10) provides durable financial resilience, enabling sustained R&D investment, stable supplier relationships, and flexible capital allocation. This structural strength reduces refinancing risk and supports operations through industry cycles.
Read all positive factors
PFIZER LIMITED (PFIZER) vs. iShares MSCI India ETF (INDA)
Market Cap
₹214.37B
Dividend Yield0.69%
Average Volume (3M)2.39K
Price to Earnings (P/E)29.9
Beta (1Y)0.57
Revenue Growth10.45%
EPS Growth-5.88%
CountryIN
Employees1,721
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)183.46
Shares Outstanding45,747,730
10 Day Avg. Volume3,328
30 Day Avg. Volume2,388
Financial Highlights & Ratios
PEG Ratio-5.08
Price to Book (P/B)5.14
Price to Sales (P/S)8.57
P/FCF Ratio19.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)182.03
Revenue Forecast (FY)₹27.44B
PFIZER LIMITED Business Overview & Revenue Model
Company Description
Pfizer Limited manufactures, markets, trades in, and exports pharmaceutical products in India and internationally. The company offers its products in various therapeutic areas, including neuro/central nervous system, hormones, cardiovascular, hemo...
How the Company Makes Money
PFIZER LIMITED primarily makes money by selling pharmaceutical products in India. Its main revenue stream is income from the sale of branded prescription medicines (and, where applicable, other healthcare products) to customers such as hospitals, ...
PFIZER LIMITED Earnings Call Summary
Earnings Call Date:Oct 28, 2024
(Q2-2025)
| % Change Since: |
Next Earnings Date:Aug 03, 2026
Earnings Call Sentiment Positive
Pfizer's earnings call reflected a strong financial performance with solid revenue and EPS growth, driven by effective cost management and advancements in the R&D pipeline. However, challenges such as impacts from the IRA Medicare Part D redesign and ongoing geopolitical uncertainties pose potential risks.Positive Updates
Strong Revenue Growth
Pfizer recorded revenues of $14.7 billion for the second quarter, representing a 10% operational increase year-over-year.
Negative Updates
Impact of IRA Medicare Part D Redesign
An $825 million year-over-year unfavorable impact due to higher manufacturer discounts resulting from the IRA Medicare Part D redesign.
Read all updates
Q2-2025 Updates
Positive
Negative
Strong Revenue Growth
Pfizer recorded revenues of $14.7 billion for the second quarter, representing a 10% operational increase year-over-year.
Read all positive updates
Company Guidance
During Pfizer's Second Quarter 2025 Earnings Conference Call, the company provided updated guidance reflecting strong year-to-date performance. Specifically, Pfizer raised its adjusted diluted EPS guidance for the full year 2025, driven by productivity gains and strategic initiatives to expand margins. The company reported second-quarter revenues of $14.7 billion, a 10% operational increase, and adjusted diluted EPS of $0.78, surpassing expectations. Pfizer's robust operating margins were achieved amidst challenges such as an $825 million unfavorable impact from higher manufacturer discounts due to the IRA Medicare Part D redesign. Pfizer's non-COVID portfolio, including strong performers like the Vyndaqel family and Eliquis, contributed significantly to its solid financial outlook. The company maintained its full-year 2025 revenue guidance of $61 billion to $64 billion and adjusted its SI&A and R&D expense forecasts while expecting an adjusted effective tax rate of approximately 13%. Pfizer's strategic focus remains on enhancing R&D productivity, leveraging AI and digital capabilities, and optimizing capital allocation to create long-term shareholder value.PFIZER LIMITED Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.75B | 25.20B | 22.81B | 21.93B | 24.25B | 26.11B |
| Gross Profit | 15.32B | 12.10B | 14.66B | 13.95B | 15.47B | 16.58B |
| EBITDA | 8.29B | 9.04B | 7.05B | 5.99B | 7.70B | 7.88B |
| Net Income | 8.39B | 7.22B | 7.68B | 5.51B | 6.24B | 6.13B |
Balance Sheet | ||||||
| Total Assets | 46.06B | 49.22B | 49.11B | 42.29B | 40.01B | 39.01B |
| Cash, Cash Equivalents and Short-Term Investments | 27.06B | 31.11B | 28.01B | 20.27B | 18.40B | 16.33B |
| Total Debt | 898.30M | 702.30M | 1.08B | 945.40M | 1.34B | 1.67B |
| Total Liabilities | 7.57B | 7.19B | 6.94B | 6.33B | 7.93B | 10.36B |
| Stockholders Equity | 38.48B | 42.03B | 42.17B | 35.96B | 32.07B | 28.64B |
Cash Flow | ||||||
| Free Cash Flow | 5.89B | 11.18B | 6.32B | 2.38B | 2.91B | 6.52B |
| Operating Cash Flow | 5.99B | 11.44B | 6.60B | 2.57B | 3.56B | 6.67B |
| Investing Cash Flow | -1.14B | -7.39B | -713.40M | -713.40M | -360.50M | -5.75B |
| Financing Cash Flow | -7.75B | -7.97B | -2.05B | -2.05B | -3.46B | -1.81B |
PFIZER LIMITED Technical Analysis
Negative
4887.30
Price Trends
4774.19
Negative
4827.99
Negative
4993.84
Negative
Market Momentum
-8.97
Negative
45.60
Neutral
38.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PFIZER, the sentiment is Negative. The current price of 4887.3 is above the 20-day moving average (MA) of 4762.36, above the 50-day MA of 4774.19, and below the 200-day MA of 4993.84, indicating a bearish trend. The MACD of -8.97 indicates Negative momentum. The RSI at 45.60 is Neutral, neither overbought nor oversold. The STOCH value of 38.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:PFIZER.
PFIZER LIMITED Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹583.25B | 35.48 | ― | 1.68% | 8.11% | 9.73% | |
71 Outperform | ₹365.86B | 27.20 | ― | 1.07% | 14.50% | 47.08% | |
71 Outperform | ₹73.55B | 18.01 | ― | 4.73% | -12.98% | -21.81% | |
69 Neutral | ₹1.13T | 25.49 | ― | 0.87% | 2.23% | -26.44% | |
69 Neutral | ₹397.70B | 37.33 | ― | 2.16% | 1.93% | 11.68% | |
64 Neutral | ₹214.37B | 29.89 | ― | 0.69% | 10.45% | -5.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:PFIZER
PFIZER LIMITED
4,685.90
-301.53
-6.05%
IN:ABBOTINDIA
Abbott India Limited
27,447.95
-3,223.41
-10.51%
IN:CIPLA
Cipla Ltd
1,399.50
-52.28
-3.60%
IN:GLAND
Gland Pharma Ltd.
2,220.60
690.45
45.12%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,347.60
-632.17
-21.22%
IN:SANOFI
Sanofi India Limited
3,193.85
-2,884.32
-47.45%
PFIZER LIMITED Corporate Events
Pfizer Limited Clears FY26 Results, Recommends Rs 75 Dividend and Sets AGM Date
May 12, 2026
Pfizer Limited’s board has approved the audited financial results for the year ended March 31, 2026, along with statements of assets, liabilities and cash flows, supported by an unmodified audit opinion from its statutory auditors. The compa...
Pfizer Limited Sets Record Date for Substantial Final Dividend Payout
May 12, 2026
Pfizer Limited’s board has recommended a final dividend of Rs 75 per equity share, representing 750% on a face value of Rs 10, for the financial year ended March 31, 2026. The move underscores the company’s strong financial performance...
Pfizer Limited Rectifies Technical Error in XBRL Financial Filing
Apr 13, 2026
Pfizer Limited has clarified a technical issue related to its XBRL submission of unaudited financial results for the quarter and half year ended 30 September 2025. The company said its board approved the results on 12 November 2025 and filings wer...
Pfizer Limited Opens Special Window for Dematerialisation of Physical Shares
Apr 8, 2026
Pfizer Limited has notified the stock exchanges that it has published newspaper advertisements informing investors about a special window for re-lodgement of transfer and dematerialization of physical securities. The window, mandated by a recent S...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.